Denali Therapeutics Inc
DNLI13.470USD
+0.030+0.22%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.96BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Denali Therapeutics Inc Unternehmen
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Unternehmensinformationen
BörsenkürzelDNLI
Name des UnternehmensDenali Therapeutics Inc
IPO-datumDec 08, 2017
CEODr. Ryan J. Watts, Ph.D.
Anzahl der mitarbeiter422
WertpapierartOrdinary Share
GeschäftsjahresendeDec 08
Addresse161 Oyster Point Blvd.
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94080
Telefon16508668547
Websitehttps://www.denalitherapeutics.com
BörsenkürzelDNLI
IPO-datumDec 08, 2017
CEODr. Ryan J. Watts, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
768.06K
+20.52%
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
383.89K
+50.87%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
+30.13%
Dr. Marc Tessier-Lavignec, Ph.D.
Dr. Marc Tessier-Lavignec, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven E. (Steve) Krognes
Mr. Steven E. (Steve) Krognes
Director
Director
--
--
Ms. Nancy A. Thornberry
Ms. Nancy A. Thornberry
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
768.06K
+20.52%
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
383.89K
+50.87%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Jul 25
Aktualisiert: Fri, Jul 25
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Baillie Gifford & Co.
8.32%
The Vanguard Group, Inc.
8.10%
Wellington Management Company, LLP
7.85%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.02%
Other
63.80%
Aktionäre
Aktionäre
Anteil
Baillie Gifford & Co.
8.32%
The Vanguard Group, Inc.
8.10%
Wellington Management Company, LLP
7.85%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.02%
Other
63.80%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
50.41%
Investment Advisor/Hedge Fund
27.07%
Hedge Fund
10.45%
Individual Investor
4.94%
Corporation
4.93%
Sovereign Wealth Fund
4.42%
Research Firm
2.34%
Pension Fund
0.51%
Bank and Trust
0.30%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
524
153.35M
105.55%
-12.15M
2025Q1
537
151.12M
104.03%
-14.77M
2024Q4
523
145.56M
100.28%
-21.13M
2024Q3
518
152.07M
106.51%
-14.19M
2024Q2
504
147.18M
103.45%
-5.80M
2024Q1
491
145.33M
102.36%
+2.75M
2023Q4
499
138.06M
99.94%
+3.21M
2023Q3
492
132.50M
96.48%
-2.55M
2023Q2
504
131.32M
95.95%
-3.31M
2023Q1
503
131.21M
95.98%
-630.06K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Baillie Gifford & Co.
12.09M
8.32%
-223.89K
-1.82%
Mar 31, 2025
The Vanguard Group, Inc.
11.77M
8.1%
-221.47K
-1.85%
Mar 31, 2025
Wellington Management Company, LLP
11.41M
7.85%
+1.56M
+15.86%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.04M
6.91%
-56.41K
-0.56%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.29M
5.02%
-712.15K
-8.90%
Mar 31, 2025
Biogen Inc
7.16M
4.93%
-5.60M
-43.89%
Oct 30, 2024
Temasek Holdings Pte. Ltd.
5.36M
3.69%
--
--
Mar 31, 2025
UBS Asset Management (Switzerland)
4.88M
3.36%
+1.49M
+43.92%
Mar 31, 2025
Capital Research Global Investors
4.77M
3.28%
-712.07K
-13.00%
Mar 31, 2025
State Street Global Advisors (US)
4.46M
3.07%
-84.22K
-1.85%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Neuroscience and Healthcare ETF
4.17%
Tema Neuroscience and Mental Health ETF
2.07%
ALPS Medical Breakthroughs ETF
1.37%
Global X Guru Index ETF
1.24%
Virtus LifeSci Biotech Clinical Trials ETF
0.84%
BNY Mellon Innovators ETF
0.47%
SPDR S&P Biotech ETF
0.43%
Global X Aging Population ETF
0.33%
iShares Health Innovation Active ETF
0.26%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
Mehr Anzeigen
iShares Neuroscience and Healthcare ETF
Anteil4.17%
Tema Neuroscience and Mental Health ETF
Anteil2.07%
ALPS Medical Breakthroughs ETF
Anteil1.37%
Global X Guru Index ETF
Anteil1.24%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.84%
BNY Mellon Innovators ETF
Anteil0.47%
SPDR S&P Biotech ETF
Anteil0.43%
Global X Aging Population ETF
Anteil0.33%
iShares Health Innovation Active ETF
Anteil0.26%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.25%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
